EU GMP injectable manufacturing plant in Spain for sale

 

1. BUSINESS OVERVIEW:

 

Company founded in 2005 by a group of professionals from the pharmaceutical sector with the aim to manufacture and distribute healthcare and medicinal products in the hospital field.

 

2. BUSINESS STRENGTHS:

 

The company complies with the EU GMP standard for injectible line and provide contract manufacturing servise to European pharmaceutical companies. 3 additional lines in ophtalmology is on the way to get EU GMP within 2017. Fornire servizi: io) Manufacturing of liquid parenteral solutions with terminal sterilization in glass, Contenitore in PP, PP bags from a 50ml to 3 litres ii) Sviluppo e analisi galenica iii) Prove di stabilità iv) Marketing, logistica e distribuzione. Vantaggi competitivi: io) tax incentives due to region in Spain, ii) nessun prestito per l'asset iii) acqua dal terreno, iv) New European machineries v) lower labor costs due to region in Spain vi) possible expansion without investment

 

3. EXPANSION OPPORTUNITY:

1. Great possibilities for geographic expansion into Spain and other European markets, Medio Oriente, Africa, Asia, Americas Market whereas EU GMP is acceptable.

 

2. 3 ophtalmology lines (1 multidose, 2 minidose) on the way to get EU GMP approval in 2017.

 

3. 90% of factory capasities are free now, so company can rapidly grow using the existing base without additional investment.

 

4. Own land is 5.000 mq, edificio 2.000 mq

 

 

4. MAIN PRODUCTS (contract manufacturing services)

 

CIPROFLOXACIN 2 MG/ML, 100 ML, 200ML (Pharmaceutical)

 

FLUCONAZOL 2 MG/ML, 50 ML (Pharmaceutical)

 

METRONIDAZOL 5 MG/ML, 100 ML (Pharmaceutical)

 

STERILE WATER, 500 ML, 1000ML, 3000ML (Medical Device, CE)

 

SOLUCION NaCl 0.9 % – 50, 100, 250, 500, 1000, 3000 ML (Medical Device, CE)

 

SOLUCION GLUCOSE 1.5 %, 3000 ML (Medical Device, CE)

 

 

 

 

 

 

 

5. MAIN CUSTOMERS:

 

Contract manufaturing servise for European pharmaceutical companies Hospitals in Spain

 

6. PROFIT AND LOSS STATEMENT, EURO
	2016	2017
TURNOVER	300.000	600.000
OPERATING EXPENSES	360.000	360.000
PROFIT / LOSS	-60.000	240.000
7. BALANCE, EURO
ASSET	3.000.000
LAND + BUILDING	1.500.000
MACHINERIES	1.500.000
NO DEBTS

 

 

8. DEBTS:

 

Nessun debito.

 

 

9. NUMBER OF EMPLOYEES: 15

10. TAX AND LABOR LIABILITIES:

 

There is no tax liability and no labor liabilities.

 

Specifically, in the Labour domain there is no action in progress.

 

 

11. PHISICAL AREA OF THE COMPANY:

 

Spagna

 

 

Terra	5.000 m²
Building	2.000 m²
Monthly Rental:	No expensas, asset belongs to the company

 

 

 

 

 

 

 

 

 

12. GENERAL INVENTORY:

 

Stock:

Machinery and Equipment Fixed assets:

 

 

 

 

 

1.500.000 Euro

 

 

 

13. REASON FOR SALE:

 

Evaluating other business opportunities.

 

 

14. SELLING PRICE AND CONDITIONS:

100% value for sale (Base date: Marzo 2017) = 5.000.000 Euro

100% Cash payment

15. ADDITIONAL INFORMATION:

Economic and financial diagnosis and company “VALUATION” when requested shall be provided during the DUE DILIGENCE, after expressions of interest from the investor group and signed Confidentiality Agreement (NDA).

 

16. SALES PROCESS:

1. Information Memorandum distribution to Pipelinepharma networking

 

2. Investor written confirmation of interest with a LOI (letter of intent) or NBO (non-binding offer)

 

3. Visit a plant, meeting sellers, Due Diligence

 

4. Binding offer

 

5. Share transfer agreement